Related Experiment Video
Updated: May 10, 2026
09:02
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Iron therapy for hepatic dysfunction in erythropoietic protoporphyria
Annals of Internal Medicine
|July 1, 1986
Summary
Oral iron therapy may prevent fatal liver failure in patients with erythropoietic protoporphyria. This treatment significantly reduced protoporphyrin levels and improved liver function in a case study.
Area of Science:
- Biochemistry
- Hepatology
- Genetics
Background:
- Erythropoietic protoporphyria (EPP) is an inherited disorder caused by ferrochelatase deficiency.
- This deficiency leads to elevated free protoporphyrin levels in red blood cells and plasma.
- EPP primarily causes photosensitivity, but hepatic failure is a severe, often fatal, complication.
Observation:
- A patient with EPP presented with abnormal liver function tests.
- The patient was treated with oral iron therapy.
- This intervention resulted in a significant reduction of protoporphyrin levels.
Findings:
- Oral iron therapy led to decreased free erythrocyte and stool protoporphyrin levels.
- The patient's liver function tests returned to normal following iron therapy.
- This suggests a potential therapeutic role for iron in managing EPP-related liver complications.
Implications:
- Iron therapy may be a viable strategy to prevent or treat hepatic failure in EPP patients.
- Further research is warranted to explore the efficacy and safety of iron supplementation in EPP.
- This finding offers a new perspective on managing a severe complication of EPP.
Related Concept Videos
01:14Erythropoiesis
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
01:22Lifecycle of Erythrocytes
Erythrocytes, also known as red blood cells, constantly move through blood capillaries. As a result, they damage their plasma membrane due to the continuous friction. Typically, after 100 to 120 days, erythrocytes become rigid and fragile as they wear out. As they pass through small vessels in the spleen and liver, they can get trapped and break apart into fragments.
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups.
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups.
01:27Disorders of Erythrocytes
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...